Gene Therapy with AdV-IL2 (TG 1021) in Unresectable Digestive Adenocarcinoma

As far as digestive adenocarcinoma are concerned, only surgical exeresis means curative treatment: for digestive unresectable adenocarcinoma, prognosis remains poor and 5 year survival rate are from 0 to 5% (1). Interesting results have been achieved throught immunotherapy but systemic use of immune drugs is limited by severe toxicity (2). To avoid toxicity of systemic immunotherapy, the idea of a local immunotherapy through gene transfer has been designed.